Leadership Team

An experienced team in the field of medical devices, business and regulatory affairs, specifically in cardiology and cardiac support.

Louis de Lillers,
CEO

Louis brings extensive experience in finance and developing or commercializing new technologies. Since taking on the role of CEO in 2015, he has transformed CorWave from a small R&D startup into a full fledge medical device scaleup. Being a self-trained computer programmer, Louis founded several ventures in the early 2000s and consequently joined Ernst&Young, where he embarked on missions with SMEs and high-growth companies. He subsequently became analyst at Clipperton Finance, a corporate finance boutique, focusing on mergers & acquisitions and venture capital transactions. He was then part of the information technology investment team at Sofinnova Partners. Prior to joining CorWave, he was co-founder and CEO of PlugMed, a medtech company developing innovative devices for LVADs and hemodialysis. Louis graduated from EDHEC Business School with a Master in Management and holds a university degree in artificial heart and circulatory support from Pitié-Salpêtrière. Louis is a board member of France Biotech, an association representing the healthcare innovation sector in France, and Start Industrie, an organization dedicated to supporting French industrial startups and scaleups.

Carl Botterbusch,
CTO

Carl brings 25 years of experience in the field of medical devices and expertise in mechanical circulatory support. He has served as Vice President of Global R&D for Teleflex Medical, a $1.5Bn healthcare firm, leading all R&D activities at 6 locations worldwide. He has also served as Vice President, R&D and General Manager, Cardiac Assist Division for Arrow International, a $500M medical device firm. His areas of expertise include mechanical cardiac support, cardiac catheters and access devices, critical care and anesthesia catheters and antimicrobial coatings. He is a degreed Mechanical Engineer and holds a Master of Business Administration. Carl provides overall technical and strategic direction to the project. He brings many years of direct experience in this field, having previously led the development of two left ventricular assist devices (LVAD), including the LionHeart, the only totally implantable LVAD to receive regulatory approval (CE Mark) to date.

Magalie Durrèche,
CFO

Before joining CorWave, Magalie Durrèche served as Chief Financial Officer, Aftersales & Circular Economy, for the entire Stellantis group. After graduating from Neoma Business School, she began her career in financial auditing at PwC before joining the Financial Consolidation teams at Sodexo. She later joined the automotive manufacturer PSA, where she held various positions within the financial department, providing her with a 360-degree view of the group’s various activities. In 2015, she was appointed Head of Investor Relations and took part in the rollout of PSA Group’s profitable growth plan “Push to Pass” to financial markets. She was promoted in 2017 to Chief Financial Officer of PSA Bank (now Stellantis Financial Services), a group generating over €1.5 billion in net banking income. In early 2020, she became Director of Consolidation and Financial Reporting and joined the project team for the merger between PSA and FCA (Fiat Chrysler Automobiles). She thus actively contributed to the formation of the New York Stock Exchange (NYSE)-listed Stellantis Group.

Paul Cornelison,
Vice President, Regulatory Affairs, Quality Assurance & Clinical Affairs

Paul brings 30 years of experience in the field of medical device regulatory affairs, quality assurance and clinical operations. Prior to joining the company, he managed 10 first-in-human trials in the USA and in Europe, conducted 5 Early Feasibility Studies (EFS) in conjunction with FDA and 5 CE Mark trials, and obtained more than 20 CE Marks and 15 Premarket Approvals (PMA) from FDA. During his 30-year career, he has gained a unique expertise in implantable cardiac devices. Former VP RAQACA of CardiAQ Valve Technologies, a transcatheter valve start-up acquired by Edwards Lifesciences for $350 million, he has also developed an extensive knowledge of cardiac assist devices (first at Arrow, then at Abbott as a consultant) and cardiac active implantable medical devices (notably at Telectronics, now Abbott’s Cardiac Rhythm Management division). He holds a Master’s degree in Engineering from the University of Pennsylvania (The School of Engineering and Applied Science, and The Wharton School).

Trevor Snyder, PhD,
Vice President, Research and Product Innovation

Trevor brings more than 20 years of experience in the research, development, and clinical engineering of mechanical circulatory support. He has authored over 20 peer-reviewed publications on medical device development and biocompatibility and has been the Principal Investigator for over $10M in National Institutes of Health and American Heart Association grants. Prior to joining CorWave, he was Vice President, R&D for VADovations, a company developing implantable blood pumps for pediatric and adult indications. Trevor previously served as a Clinical Engineer at three VAD programs, INTEGRIS Health, University of Maryland Medical Center, and the University of Pittsburgh Medical Center, supporting over 600 VAD patients on over a dozen types of VADs and Artificial Hearts. He has conducted pre-clinical biocompatibility testing on over 25 medical devices, including 12 different VADs. Trevor received a Bachelor’s degree in Biomedical Engineering from Tulane University and holds a PhD in Bioengineering from the University of Pittsburgh.

Michael Webb,
Vice President, Manufacturing

Michael brings over 15 years of LVAD manufacturing expertise to CorWave. Mechanical Engineer by background, he has worked on the process development and manufacturing of two different companies in the mechanical circulatory support space. These efforts contributed to the support of over 18,000 heart failure patients around the world. In the early 2000s, he helped transferring the VentrAssist cardiac assist system from R&D to production as part of the launch of clinical trials in Europe, Australia and the United States. He then joined HeartWare where he contributed to the ramp-up of HVAD production, from the first commercial implants (a few hundred units per year) to fully-fledged production (several thousand units per year), leading the expansion of the Florida-based cardiac pump manufacturing plant. He was Director of Operations Engineering at HeartWare when the company was acquired for $1.1 billion by Medtronic.

Charlotte Rasser, PhD,
Senior Strategy & Scientific Affairs Manager

 Charlotte joined CorWave in 2018 as Strategic Partnerships Project Leader, in charge of the CALYPSO €14 million R&D collaborative program conducted with clinical and scientific teams of Lille University Hospital and Pitié-Salpêtrière University Hospital (AP-HP). Prior to joining CorWave, she completed a PhD on coronary and intracranial stents at the Laboratory for Vascular Translational Science (Bichat AP-HP Hospital and Paris Diderot University) in partnership with Balt, a high growth medtech company. A graduate from Ecole Polytechnique, Charlotte holds a Master’s degree in Materials Science from the University of Cambridge and a Certificate in Business Administration from Sorbonne Paris Cité University.